Cargando…
Optimal clinical trial designs for immune-based therapies in persistent viral infections
There is now effective therapy for infection by the Human Immunodeficiency Virus (HIV), but there is no cure. Consequently, antiviral drugs must be administered continuously to suppress viral replication. Recently, a large phase III international immune-based therapy trial was discontinued because i...
Autor principal: | Smith, Kendall A |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2002
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC149407/ https://www.ncbi.nlm.nih.gov/pubmed/12459051 http://dx.doi.org/10.1186/1476-9433-1-4 |
Ejemplares similares
-
Operation of mitochondrial machinery in viral infection-induced immune responses
por: Lai, Jenn-Haung, et al.
Publicado: (2018) -
Host tolerance contributes to persistent viral shedding in COVID-19
por: Chang, De, et al.
Publicado: (2020) -
Persistent viral RNA shedding in COVID-19: Caution, not fear
por: Plebani, Mario
Publicado: (2021) -
The Challenge of Viral Immunity
por: Doherty, Peter C., et al.
Publicado: (2007) -
Considerations and guidance in designing equity-relevant clinical trials
por: Mbuagbaw, Lawrence, et al.
Publicado: (2017)